SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City on Thursday, October 3, 2019 at 5:20 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events and an archived replay will be accessible for up to 30 days.
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola ECTM.
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications